Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1657 Inhibitors

Olr1657 inhibitors represent a specialized class of chemical compounds that interact with the Olr1657 receptor, a type of olfactory receptor. Olfactory receptors are G-protein-coupled receptors (GPCRs) that play a crucial role in the detection of odorant molecules, leading to the perception of smell. The Olr1657 receptor, like other olfactory receptors, is embedded in the cell membranes of olfactory neurons, where it binds to specific ligands or odorant molecules. Inhibitors of Olr1657 are designed to interfere with the normal functioning of this receptor, thereby blocking or modulating the receptor's activity. This can result in alterations to the olfactory signaling pathways, leading to changes in how certain odorants are perceived. The design and synthesis of Olr1657 inhibitors require a deep understanding of the receptor's structure, particularly its binding site, to create molecules that can effectively bind and inhibit the receptor without triggering downstream signaling.

The study of Olr1657 inhibitors extends into the exploration of their effects on the broader olfactory system, as inhibiting a single receptor can have cascading effects on olfactory perception. This receptor-specific inhibition can serve as a valuable tool in the study of olfactory coding, where the relationship between receptor activation and odor perception is examined. By selectively inhibiting Olr1657, researchers can dissect the role of this receptor in recognizing specific odorants and its contribution to the overall olfactory experience. Additionally, Olr1657 inhibitors can be used in studies focused on receptor desensitization and the adaptive mechanisms of the olfactory system. The chemistry behind these inhibitors often involves the development of small molecules with high specificity for the Olr1657 receptor, leveraging structure-activity relationships (SAR) and molecular modeling to optimize binding affinity and selectivity. The ability to selectively target Olr1657 with these inhibitors provides a powerful means to manipulate olfactory signaling pathways in a controlled experimental setting, contributing to the broader understanding of olfactory receptor function and signaling mechanisms.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Targets BCR-ABL tyrosine kinase, may disrupt cell signaling in leukemia cells.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, may affect cell proliferation in melanoma by blocking MAPK/ERK pathway.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, potentially affecting cell growth in breast cancer.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

BTK inhibitor, may disrupt B-cell receptor signaling in lymphomas.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, could block cell cycle progression in breast cancer.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/2 inhibitor, potentially influencing cytokine signaling in myelofibrosis.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, may impair NF-κB pathway in multiple myeloma.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

EGFR inhibitor, could inhibit cell proliferation in non-small cell lung cancer.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, may induce apoptosis in chronic lymphocytic leukemia.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL tyrosine kinase inhibitor, potentially disrupting cell signaling in chronic myeloid leukemia.